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Abstract. Finding tumour genetic markers is essential to biomedicine due to their
relevance for cancer detection and therapy development. In this paper, we explore a
recently released dataset of chromosome rearrangements in 2,586 cancer patients,
where different sorts of alterations have been detected. Using a Random Forest
classifier, we evaluate the relevance of several features (some directly available in
the original data, some engineered by us) related to chromosome rearrangements.
This evaluation results in a set of potential tumour genetic markers, some of which
are validated in the bibliography, while others are potentially novel.
Keywords. cancer research, chromosomal rearrangements, tumour genetic markers,
Random Forest
1. Introduction
Cancer is among the four current leading causes of death before the age of 70, having
around 18.1 million deaths in 2018 [1]. For this reason, studying and understanding the
biology of tumours constitutes a priority in biomedicine. One of the leading research
lines on this field is the study of chromosomal rearrangements in solid tumour cells.
Chromosomal rearrangements (or breaks) are changes in the basic structure of a chromo-
some, examples of such alterations are the deletion, duplication or reordering of a subset
of genes of the chromosome.
Several studies have shown that the presence of chromosomal rearrangements in tu-
mours is often correlated with poor prognosis [2,3], and some of them have been identi-
fied as hallmarks of several tumour types. This implies that the presence of some specific
gene expressions or DNA changes, like chromosomal rearrangements, can be used as
tumour markers to characterize different types of cancer. Finding these markers can be
useful in several ways, like predicting disease outcome or response to treatment. Some
examples of chromosomal rearrangements as tumour genetic markers are mutations of
chromosome 5q21 on colorectal cancer [4] or deletions on chromosome 3p on lung can-
cer [5].
In this paper, we present a new methodology to find potential tumour genetic mark-
ers from a dataset of chromosomal rearrangements. This data consists of a set of files,
each one of them from a patient, where we have a sequence of rearrangements, repre-
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Figure 1. Summary of the data pipeline.
sented as triplets source base pair, destiny base pair and rearrangement type. From these
sequences of triplets, we engineer several features related to the chromosomal rearrange-
ments, and then, use a Random Forest as a feature extractor. In this way, we generate a
ranking of the features by their importance. The best features of the ranking are new po-
tential genetic markers found by the methodology. In our experiments, we extract more
than thirty potential markers. Figure 1 shows the basic data pipeline used on this work.
2. Data
The data used in this study comes from genetic cancer data from the PanCancer Anal-
ysis of Whole Genomes (PCAWG) project [6]. The PCAWG study is an international
collaboration to identify common patterns of mutation in more than 2,800 cancer whole
genomes from the International Cancer Genome Consortium. Let us remark that scien-
tific works with a primary focus on pan-cancer are under publication embargo until July
25, 2019. For this reason, there is no comparison of our results with similar approaches.
This situation also guarantees the novelty of all our experiments.
Using an in-house pipeline designed to analyse tumour genomes in a clinical and re-
search context, we have identified breakpoints that inform of sites of genomic and chro-
mosomal rearrangements in the PCAWG data. This pipeline identifies breakpoints using
the information of reads, and paired-end reads mapping from whole-genome sequencing,
using Burrows-Wheeler Aligner (BWA). These predictions have passed strict filtering,
ensuring a high-quality set of variants.
Our data is composed of 2,586 patients (samples), where each patient has a vari-
able number of breaks (features). In this dataset there are 21 possible types of cancer
(e.g., breast cancer, liver cancer, pancreas cancer, etc. ). At the same time, every sample
comes from one of four possible germ layers (i.e., basic cell types). The germ layers
are ECTODERM, ENDODERM, MESODERM and NEURAL CREST. In this study we
consider 4 types of chromosomal breaks: deletions (DEL), translocations (TRA), dupli-
cations (DUP) and two kinds of inversions (t2tINV and h2hINV).
The total length of the human genome is over three billion base pairs. Those pairs
are divided into 24 chromosomes. Characterizing breaks at a base pair level would end
up with very sparse data on a high dimensional space (2,586 samples over 3 billion
pairs). For this reason, we choose to reduce the granularity of the features used, working
instead at chromosome level (e.g., instead of considering a deletion on the gene 15p5,
we consider a deletion on chromosome 15). As a result, we end up with 2,586 samples
over the 24 chromosomes.
We use the germ layers as a generalization of the cancer types because of the small
number of data samples, but with more data, this methodology could extract the markers
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ECTODERM ENDODERM MESODERM NEURAL CREST
Biliary 0 34 0 0
Bladder 0 23 0 0
Bone/SoftTissue 0 0 92 0
Breast 209 0 0 0
CNS 0 0 0 261
Cervix 0 0 20 0
Colon/Rectum 0 60 0 0
Esophagus 0 87 0 0
Head/Neck 0 0 56 0
Kidney 0 0 176 0
Liver 0 322 0 0
Lung 0 84 0 0
Lymphoid 0 0 197 0
Myeloid 0 0 29 0
Ovary 0 0 112 0
Pancreas 0 306 0 0
Prostate 0 263 0 0
Skin 0 0 0 106
Stomach 0 72 0 0
Thyroid 0 30 0 0
Uterus 0 0 47 0
Total 209 1281 729 367
Table 1. Number of samples for every cancer type on the dataset, with their corresponding germ layer.
for every cancer type. Table 1 shows how many samples are in the dataset for each cancer
type, and how are these samples distributed over the germ layers.
2.1. Preprocessing
The first pre-processing step performed on the data was to remove all the patients with
no germ layers nor cancer type labels available. After removing these unlabelled sam-
ples, we extracted a set of features from additional metadata available in the dataset (see
the bottom part of Table 2) and engineered another set (see the top part of Table 2). The
engineered features are related to the kind of breaks or their position in the DNA. Fea-
tures include, among others, the number of rearrangements on every chromosome or the
number of rearrangements of each type.
Metadata include gender, age, tumour stage1 and tumour stage2 as features and
germ layer as target variable (i.e., label). The last two features stand for the clinical stage
of the tumour (non-genetic information). We initially had two options to select as target
variable: the cancer type and the germ layer. Ideally, we would have selected cancer type
but, the number of samples (2,586) w.r.t. the high number of cancer types (21) makes
the problem unfeasible. For this reason, we end up selecting the germ layer instead of
as a generalization of the cancer type. The final set of features (engineered and metadata
features) as shown in Table 2 accompanied by a brief description.
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Genetic Data Num. Features
# of breaks No. of breaks of the sample. 1
DUP, DEL, TRA No. of breaks per break type. 3
h2hINV, t2tINV No. of breaks per inversion type. 2
chr 1, ..., chr Y No. of breaks per chromosome. 24
DEL 1, ..., DEL Y No. of deletions per chromosome. 24
DUP 1, ..., DUP Y No. of duplications per chromosome. 24
TRA 1, ..., TRA Y No. of translocations per chromosome. 24
h2hINV 1, ..., h2hINV Y No. of h2h inversions per chromosome. 24
t2tINV 1, ..., t2tINV Y No. of t2t inversions per chromosome. 24
prop {chr n, ..., t2tINV n} For each break type, for each chromosome, 149
proportion of breaks over total breaks in patient.
Patient Metadata
female Gender of the patient, 1 if female and 0 otherwise. 1
donor age Age of the patient. 1
ts 1 category Methastasic, Primary or Recurrent 3
ts 2 category NOS, bone marrow, periphleal blood, derived from 9
tumour, methastasis to lymph node, methastasis
to distant location, other or solid tissue
Total number of features 313
Table 2. Genetic features (top) and metadata features (bottom) extracted from the dataset.
After the extraction of these features, we perform a one-hot-encoding over all cat-
egorical features (both tumour stages). Furthermore, we impute 119 missing values for
the age feature using the Multivariate Imputation by Chained Equations (MICE) [7].
Data was split into two partitions. One for training the model and another one for
testing the classification results. The partition was stratified w.r.t. the germ layers, in
order to try to maintain their original distribution (Table 1). This way, we obtained a
training partition with 2,068 samples and a test partition with 519 samples. Both of them
containing 313 features, including boolean features from the one-hot-encoding.
3. Approach
On this study, a Random Forest model [8] was used to identify which chromosomal rear-
rangements, and in which location, contain genetic markers. Random Forest has shown
to have good performance over many applications, is one of the more interpretable mod-
els among the current machine learning state of the art, and it is capable of providing
feature importance after training it. These properties make it a good candidate for the
computational biology field, both as a classification or feature selection tool [9,10].
We trained the Random Forest using the set of 313 features extracted from the chro-
mosomal rearrangement data and the patient metadata (see Table 2). The result of train-
ing this model is the feature importance order (where the best features are positioned at
the beginning, and the worse are positioned at the end) and the classification results.
In the first experiment, the feature importance orders obtained from training 300
Random Forest were used, each one containing 100 Decision Tree classifiers, to gen-
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Hyperparameter Distribution Best Value
max depth uni f (2,20) 13
min samples split uni f (2,11) 5
min samples leaf uni f (1,20) 3
bootstrap unif ([True, False]) True
criterion unif ([gini, entropy]) entropy
max features unif ([auto, log2, None]) None
class weight - balanced
n estimators - 100
Table 3. Distributions used on the random search cross-validation and the best hyperparameters selected for
the Random Forest.
erate our aggregated feature ranking. This large number provides additional robustness
to the aggregated feature ranking. The aggregated ranking was used to extract the most
important features. These will be our potential genetic markers.
In the second experiment, this process was repeated four times, discriminating each
germ layer type against all the rest (i.e., one vs all). Four new rankings representing the
best features (i.e., potential genetic markers) for each one of the specific germ layers
were obtained.
4. Experiments
All Random Forest models target to classify the patients by the germ layer associated
with their cancer. This classification has two outputs of interest: the feature importance
and classification results. The feature importance order extracts the relationships between
the features and the germ layers, while classification results prove that these results are
relevant.
To estimate the hyperparameters of the Random Forest, Random Search Cross-
Validation [11] was used, with three validation partitions and the parameter distributions
presented in Table 3. Those hyperparameters were tuned for the four class classification
task (i.e., all vs all), and fix their value on all further experiments.
4.1. Feature ranking generation
Since Random Forest feature selection has a certain level of stochasticity, we first assess
the stability of the method by performing 300 independent runs. We compute the mean
ranking of all features as an indicator of robustness. Results (shown in Table 4) indi-
cate a very strong consistency among runs, which speaks for the relevance of all further
experiments.
4.2. Germ layer specific ranking generation
To obtain a feature ranking specific for each germ cell, the Random Forest was trained to
discriminate every germ layer from the other three, transforming the original multi-class
problem with four germ layers into four binary problems classifying the target germ layer
vs the other three (e.g., ENDODERM vs NON-ENDODERM).
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Ranking Mean position Features
1 1.000 donor age at diagnosis
2 2.000 female
3 3.000 tumour stage1 Primary tumour
4 4.018 tumour stage2 solid tissue
5 4.992 DEL
6 7.200 tumour stage2 other
7 7.478 chr 8
8 7.500 TRA
9 7.914 number of breaks
10 10.518 proportion DUP
11 10.910 proportion DEL
12 12.448 tumour stage2 lymph node
13 12.728 proportion chr 9
14 15.136 t2tINV
15 16.184 proportion DEL 14
Table 4. The 15 most characteristic features found by the 300 Random Forest runs. The second column con-
tains the mean position of each feature over the 300 executions.
After transforming the data labels, we train 300 Random Forests for each germ layer
and aggregate these rankings (see the details in Section 4.1). This way, we obtain four
rankings, with the most discriminating features for each one of the germ layers.
The results obtained (see Table 5) show different feature rankings for every classifi-
cation experiment, especially on the chromosome related features. These results suggest
that the presence or the type of rearrangements on specific chromosomes are related with
the germ layer of the cancer cell.
4.3. Classification results
To have some intuition about the importance of the features extracted by the model and
their relation with the data, the model was tested using different sets of the best features
of the ranking. We report classification results using the best 5, 15, 25, 50, 100, and all
313 features based on its importance ranking (reported in Table 6). Best F1 measure is
obtained by using the best 25 features in most of the experiments.
5. Query-based evaluation
The validation of the results obtained in the previous sections is not straight-forward. It
will require thorough analysis from medical experts, in order to validate the existence
of genetic markers associated with the identified features. This process can take from
months to years.
In order to produce the first evaluation of the produced results, we use a crowd-based
approach based on state of the art on cancer research. The well-known Medical Subject
Headings [12] was used, which indexes medical papers from PubMed [13]. PubMed
allows querying over 29 million medical abstracts from MEDLINE, life science journals,
and online books. Through its search engine, it is possible to find the number of papers
May 2019
Rank All Germ ECTODERM NEURAL CREST MESODERM ENDODERM
1 donor age female donor age donor age donor age
2 female donor age ts1 Primary ts2 blood female
3 ts1 Primary ts2 solid tissue prop DUP ts2 lymph node DEL
4 ts2 solid tissue TRA chr 21 DEL ts2 solid tissue
5 DEL chr 8 prop chr 9 prop TRA 5 # of breaks
6 ts2 other prop h2hINV 19 chr 5 female TRA
7 chr 8 TRA 17 prop chr 2 # of breaks ts2 lymph node
8 TRA prop DEL 4 prop DUP 12 chr 19 ts2 other
9 # of breaks t2tINV ts2 solid tissue prop chr 3 ts1 Primary
10 prop DUP prop TRA 17 chr 6 ts1 Primary ts2 blood
11 prop DEL prop DEL prop chr 5 prop chr 9 prop TRA 5
12 ts2 lymph node prop chr 9 ts2 lymph node prop t2tINV prop DEL
13 prop chr 9 prop chr 5 chr 1 ts2 solid tissue prop chr 1
14 t2tINV prop chr 4 DEL 1 ts1 Metastatic prop DUP
15 prop DEL 14 prop TRA 9 prop chr 21 prop TRA prop chr 4
Table 5. Best 15 features found for each classification experiment. The second column (All Germ) shows the
best features for the all vs all classification task; this column corresponds with the results on Table 4. Third to
the sixth column shows the best features for the one vs all classification task.
F1 All Germ F1-ECTO. F1-NEURAL. F1-MESO. F1-ENDO.
All 0.694 0.420 0.877 0.649 0.830
100 0.709 0.494 0.839 0.664 0.840
50 0.722 0.543 0.859 0.660 0.826
25 0.741 0.556 0.887 0.681 0.841
15 0.737 0.551 0.879 0.682 0.834
5 0.630 0.404 0.818 0.565 0.731
Table 6. Classification results using the top 5, 15, 50 and 100 features, or all of them. The second column (F1
All Germ) shows the mean F1 measure for the all vs all classification task. Third, to the sixth column show the
F1 measure for the one vs all classification task. Best results in bold.
mentioning both a cancer type (e.g., Pancreas) and a chromosome. The result of this
search can give an idea of the current medical knowledge regarding the relationship
between a type of cancer and a chromosome.
The obtained features are trained to discriminate germ layers. However, most medi-
cal papers do not work at this granularity. Instead, cancer type queries produce larger, and
thus more representative results. For this reason we can only use this evaluation method
reliably on the ECTODERM germ type, which only contains one cancer type (breast).
The other germ types contain several cancer types on variable proportions. On the other
hand, the engineered features are not appropriate for a straight-forward query on med-
ical papers. These are often too specific (e.g., proportion of h2h inversions on chromo-
some 19). For this reason, we limit ourselves to evaluate the relation found with whole
chromosomes, disregarding any further particularity of the feature (e.g., chromosome 19,
instead of the proportion of h2h inversions on chromosome 19).
In particular, 24 queries were performed. One for each chromosome, together with
the term for breast cancer. Since not all chromosomes are expected to be related to
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breast cancer, not all queries will be relevant. We focus on the top three chromosomes
related to breast cancer by the number of returned results. These are chromosomes 17,
11 and 8. At the same time, we find the top three chromosomes associated with a feature
discriminating breast cancer on our results. These are chromosomes 8, 19 and 17 (chr 8,
prop h2hINV 19 and TRA 17).
Remarkably, two of the three mentioned chromosomes on papers related to breast
cancer, are involved in two of the three most relevant features we found for discrimi-
nating the ECTODERM germ layer (i.e., breast cancer). This combination has a random
statistical probability of roughly 1%.
6. Discussion
The results that are shown in this work open up several questions. To start with, the query-
based evaluation finds two of the top three chromosomes related to breast cancer to be
consistent with the literature (see §5). However, what is happening with those missing?
The chromosome found by the model, but not in the literature, is chromosome 19.
This could be either a mistake by the model or an unexplored relation by the medical
community. This is precisely the sort of relation with potential impact in the medical
domain, as previously unknown genetic markers could be contained in this chromosome.
The chromosome found in the literature, but not by the model, is chromosome 11.
This behaviour can be a consequence of its relevance for certain MESODERM cancer
types (Kidney, where it is the first chromosome in several papers, or Ovarian, where it is
the second). This, in turn, affects the Random Forest model, since this chromosome will
not be discriminative for ECTODERM, even though it may be representative.
The absence of chromosome 11 in our results brought to our attention a couple of
limitations on our approach. The first is related to the use of a classifier for extracting
feature information. A classifier focuses on the discriminability of features. This might
cause the model to oversee features that, while being representative for a particular type
of cancer, are not discriminant in the context of several cancer types. This problem might
be mitigated by doing pairwise classification instead of one vs all, comparing pairs of
cancer types. By doing so, all features that are discriminant for our target cancer type
with regards to any of the other cancer types would be identified.
The complete, and unfeasible, solution to this problem would be to have a healthy
person sample to compare against. However, healthy genomes do not have chromosomal
rearrangements. As such, a healthy sample would be empty and impossible to compare
against.
7. Conclusions
The results presented in this paper target the guidance of genetic markers. Given the large
granularity of features used in our approach, this is not a straight-forward process from
the medical perspective. To provide some evidence on the consistency of our approach,
we performed a partial, query-based validation against an extensive database of medical
papers. In this evaluation, we found that, out of the top three chromosomes identified
with breast cancer in the literature, two are also found by the method. This coincidence
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has a random statistical probability of roughly 1%. This gives us proportional confidence
in asserting that the features found by our models are useful guidelines for cancer ge-
netic markers. There is other evidence highlighting the medical consistency of our find-
ings. For example, the most reliable feature for discriminating ECTODERM (i.e., breast
cancer) is gender.
Another interesting insight from Table 5 is that different germ layers seem to be
related to different break types. While translocations are the most relevant break type
for ECTODERM, for MESODERM and ENDODERM deletions seem to be more rel-
evant. The NEURAL CREST case deserves a specific commentary. This cancer type is
frequently related to children, in particular, Central Nervous System cancer (CNS). Chil-
dren develop cancer differently when compared to adults. Our intuition is that chromo-
somal duplication is more consistent with the growth patterns of children, which would
explain the findings of our model.
The same Table 5 also displays a remarkable correlation between the specificity
of a germ layer (i.e., how many different cancer types it contains) and the specificity
of the features found by our model. On the one hand, the most specific germ layers
(ECTODERM and NEURAL CREST, with only one and two cancer types) have between
5 and 6 chromosome specific features among the top 10 ranked. On the other, the most
generic germ layers (ENDODERM and MESODERM) and the all vs all classification
(All Germ) have between zero and two chromosome specific features on the top 10. This
seems to indicate that specific cancer types could be characterized further if more detail
became available for analysis.
Randomized Decision Trees build inside the Random Forest algorithm, are among
the fastest machine learning models for classification, with a complexity of O(KNlogN)
[14]. An essential feature of our model and methodology is thus its high scalability. If
more data becomes available, we could extract more specific markers for one or more
cancer types with a minimal computational cost. Beyond being scalable, the method is
also robust to high-dimensional and sparse domains, since we treated these appropriately.
Notice the actual train data set has 313 features for 2,068 samples, with a 92% of zero
values. In this case, the model design was tuned explicitly for this setting, including a
large number of decision trees on each random forest, and a large number of random
forests to be aggregated.
Summarizing the results obtained on this paper; we have obtained potential general
markers that could be related to tumour-genesis on the four basic germ layer types. We
have found specific potential markers for every one of the significant germ layers, obtain-
ing coherent results respect to the known bibliography on the subject. Finally, we have
obtained a general method for genetic marker mining, that could be generalized by the
growth of the dataset. The continuation of this work requires extensive experimentation
by medical experts in order to test and validate our many hypotheses.
Acknowledgements
This work is partially supported by the Joint Study Agreement no. W156463 under the
IBM/BSC Deep Learning Center agreement, by the Spanish Government through Pro-
grama Severo Ochoa (SEV-2015-0493), by the Spanish Ministry of Science and Technol-
ogy through TIN2015-65316-P project, and by the Generalitat de Catalunya (contracts
May 2019
2017-SGR-1414). Pro. U. Corte´s is a member of the Sistema Nacional de Investigadores
(Level III) (SNI-III). Me´xico. We would like to thank MD. Adria´n Puche Gallego and
PhD. Davide Cirillo for useful discussions and guidance.
References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.,”
CA: a cancer journal for clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] J. W. Albertson, Donna G., Collins, Colin, McCormick, Frank, Gray, “Chromosome aberrations in solid
tumors,” Nature Genetics, vol. 34, no. 4, pp. 369–376, 2003.
[3] M. N. H. Luijten, J. X. T. Lee, and K. C. Crasta, “Mutational game changer: Chromothripsis and its
emerging relevance to cancer,” Mutation Research - Reviews in Mutation Research, vol. 777, no. March,
pp. 29–51, 2018.
[4] I. Nishisho, Y. Nakamura, Y. Miyoshi, Y. Miki, H. Ando, A. Horii, K. Koyama, J. Utsunomiya, S. Baba,
and P. Hedge, “Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients,” Science,
vol. 253, no. 5020, pp. 665–669, 1991.
[5] J. Whang-Peng, C. Kao-Shan, E. Lee, P. Bunn, D. Carney, A. Gazdar, and J. Minna, “Specific chro-
mosome defect associated with human small-cell lung cancer; deletion 3p(14-23),” Science, vol. 215,
no. 4529, pp. 181–182, 1982.
[6] K. Zhang and H. Wang, “Cancer Genome Atlas Pan-cancer analysis project,” Chinese Journal of Lung
Cancer, vol. 18, no. 4, pp. 219–223, 2015.
[7] S. v. Buuren and K. Groothuis-Oudshoorn, “mice: Multivariate imputation by chained equations in r,”
Journal of statistical software, pp. 1–68, 2010.
[8] F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer,
R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, and E. Duch-
esnay, “Scikit-learn: Machine learning in Python,” Journal of Machine Learning Research, vol. 12,
pp. 2825–2830, 2011.
[9] Y. Qi, “Ensemble Machine Learning,” Ensemble Machine Learning, pp. 307–323, 2012.
[10] R. Dı´az-Uriarte and S. Alvarez de Andre´s, “Supplementary material for Gene selection and classification
of microarray data using random forest,” BMC Bioinformatics, vol. 7, pp. 1–73, 2005.
[11] J. Bergstra and Y. Bengio, “Random search for hyper-parameter optimization,” vol. 13, pp. 1–25, 2012.
[12] “Mesh: The nlm controlled vocabulary thesaurus used for indexing articles for pubmed..” https://
www.ncbi.nlm.nih.gov/mesh.
[13] “Pubmed: Citations for biomedical literature from medline, life science journals, and online books..”
https://www.ncbi.nlm.nih.gov/pubmed.
[14] G. Louppe, “Understanding random forests: From theory to practice,” arXiv preprint arXiv:1407.7502,
2014.
